Kos Pharmaceuticals Release: Niaspan(R) Combined with Low/Moderate Dosed Statin Achieves Better Total Lipid Control Vs. Higher Dose Statin Monotherapy Or Zocor(R)/Zetia(R)

CRANBURY, N.J.--(BUSINESS WIRE)--June 20, 2006--Kos Pharmaceuticals, Inc. (Nasdaq: KOSP - News): Kos Pharmaceuticals, Inc. (Nasdaq: KOSP - News) commented today on the results from the COMPELL (COMParative Effects on Lipid Levels of Niaspan and Statins Versus Other Lipid Therapies) Phase IV efficacy trial presented at the XIV International Symposium on Atherosclerosis. The results demonstrated that adding the HDL-boosting therapy Niaspan (niacin extended-release tablets) to statin therapy (HMG-CoA reductase inhibitors) achieved superior raising of high-density lipoprotein cholesterol (HDL-C), or “good” cholesterol, and increased triglyceride lowering, with equivalent lowering of low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, for patients compared to treatment with a high dose statin or Zocor/Zetia (simvastatin and ezetimibe).(1)